Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SCD | O00767 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28029866 | 0.84 | APP (0.53) | APPGLAGAASULT1A1RAB9A | |
| SCHEMBL3614565 | 0.81 | RAB9A (0.57) | APPGAASULT1A1RAB9AMEN1 | |
| SCHEMBL8536132 | 0.80 | APP (0.63) | APPGLAGAASULT1A1RAB9A | |
| SCHEMBL9396448 | 0.79 | POLB (0.55) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL11972685 | 0.79 | APP (0.58) | APPGLAGAASULT1A1RAB9A | |
| SCHEMBL1983051 | 0.79 | APP (0.58) | APPGLAGAASULT1A1RAB9A | |
| SCHEMBL2195686 | 0.78 | SCD (0.54) | APPGLAGAARAB9AMEN1 | |
| SCHEMBL13853571 | 0.77 | APP (0.67) | APPGLAGAASULT1A1SCD | |
| SCHEMBL1982639 | 0.76 | APP (0.66) | APPGLAGAASULT1A1SCD | |
| SCHEMBL1986918 | 0.76 | APP (0.56) | APPGLAGAASULT1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9468694-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2016-10-18 | — | — | US | disclosed |
| US-9468694-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2016-10-18 | — | — | US | disclosed |
| US-9468694-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2016-10-18 | — | — | US | disclosed |
| US-20150328344-A1 | Fluorination Process | GE HEALTHCARE AS (NO) | 2015-11-19 | — | — | US | disclosed |
| US-20150328344-A1 | Fluorination Process | GE HEALTHCARE AS (NO) | 2015-11-19 | — | — | US | disclosed |
| US-20150328344-A1 | Fluorination Process | GE HEALTHCARE AS (NO) | 2015-11-19 | — | — | US | disclosed |
| US-9126961-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| US-9126961-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| US-9126961-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| EP-1915330-B1 | FLUORINATION PROCESS OF ANILIDE DERIVATIVES AND BENZOTHIAZOLE FLUORINATE DERIVATIVES AS IN VIVO IMAGING AGENTS | GE HEALTHCARE LTD (GB) | 2014-12-10 | — | — | EP | disclosed |
| US-20130225829-A1 | FLUORINATION PROCESS | GE HEALTHCARE AS (NO) | 2013-08-29 | — | — | US | disclosed |
| US-20130225829-A1 | FLUORINATION PROCESS | GE HEALTHCARE AS (NO) | 2013-08-29 | — | — | US | disclosed |
| US-8410312-B2 | Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents | GE HEALTHCARE LIMITED (GB) | 2013-04-02 | — | — | US | disclosed |
| US-8410312-B2 | Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents | GE HEALTHCARE LIMITED (GB) | 2013-04-02 | — | — | US | disclosed |
| US-8410312-B2 | Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents | GE HEALTHCARE LIMITED (GB) | 2013-04-02 | — | — | US | disclosed |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | GE HEALTHCARE LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | GE HEALTHCARE LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | GE HEALTHCARE LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| EP-1915330-A1 | FLUORINATION PROCESS OF ANILIDE DERIVATIVES AND BENZOTHIAZOLE FLUORINATE DERIVATIVES AS IN VIVO IMAGING AGENTS | GE Healthcare Limited (GB) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007020400-A1 | FLUORINATION PROCESS OF ANILIDE DERIVATIVES AND BENZOTHIAZOLE FLUORINATE DERIVATIVES AS IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328344-A1 | Fluorination Process | CYP2F1, C1R, C1S | APP 1584/4885GLA 1415/4885GAA 1685/4885 |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | Q6ZSR9, AFF1, F9 | APP 2690/4885GLA 3038/4885GAA 1921/4885 |
| US-20130225829-A1 | FLUORINATION PROCESS | CYP2F1, C1R, C1S | APP 1584/4885GLA 1415/4885GAA 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.